Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank Disease ID
1 Acute myeloid leukemia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
2 Adipocytokine signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
3 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
4 African trypanosomiasis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
5 African trypanosomiasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
8 Alcoholic liver disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Allograft rejection 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
10 Alzheimer disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
11 Alzheimer disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
12 Amoebiasis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
13 Amoebiasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
14 Amoebiasis 💬
[2] IL1R1, IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
15 AMPK signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
16 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
17 Antigen processing and presentation 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
18 Apelin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
19 Autophagy - animal 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
20 Autophagy - other 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
21 Breast cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
22 C-type lectin receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
23 Cellular senescence 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
24 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
25 Chagas disease 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
26 Chagas disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 Chemical carcinogenesis - receptor activation 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
28 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
29 Chemokine signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
30 Choline metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
31 Cholinergic synapse 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
32 Colorectal cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
33 Coronavirus disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
34 Coronavirus disease 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
35 Coronavirus disease 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
36 Cytokine-cytokine receptor interaction 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
37 Cytokine-cytokine receptor interaction 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
38 Cytokine-cytokine receptor interaction 💬
[2] IL1R1, IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
39 Cytokine-cytokine receptor interaction 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
40 Cytosolic DNA-sensing pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
41 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
42 Efferocytosis 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
43 Epstein-Barr virus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
44 ErbB signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
45 Fluid shear stress and atherosclerosis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
46 Fluid shear stress and atherosclerosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
47 Fluid shear stress and atherosclerosis 💬
[2] IL1R1, IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
48 Folate biosynthesis 💬
[2] DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
49 Folate biosynthesis 💬
[2] DHFR, DHFR2 💬 Methotrexate sodium 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
50 Folate transport and metabolism 💬
[2] DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
51 Folate transport and metabolism 💬
[2] DHFR, DHFR2 💬 Methotrexate sodium 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
52 Gastric cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
53 Glioma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
54 Graft-versus-host disease 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
55 Graft-versus-host disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
56 Growth hormone synthesis, secretion and action 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
57 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
58 Hematopoietic cell lineage 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 Hematopoietic cell lineage 💬
[2] IL1R1, IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
60 Hematopoietic cell lineage 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
61 Hepatitis B 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
62 Hepatitis C 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
63 Hepatitis C 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
64 Hepatocellular carcinoma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
65 Herpes simplex virus 1 infection 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
66 Herpes simplex virus 1 infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
67 Herpes simplex virus 1 infection 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
68 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
69 HIF-1 signaling pathway 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
70 HIF-1 signaling pathway 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
71 HIF-1 signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
72 Hormone signaling 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
73 Human cytomegalovirus infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
74 Human cytomegalovirus infection 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
75 Human cytomegalovirus infection 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
76 Human cytomegalovirus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
77 Human cytomegalovirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
78 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
79 Human papillomavirus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
80 Human papillomavirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
81 Human T-cell leukemia virus 1 infection 💬
[2] IL1R1, IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
82 Human T-cell leukemia virus 1 infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
83 Huntington disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
84 IL-17 signaling pathway 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
85 IL-17 signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
86 Inflammatory bowel disease 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
87 Inflammatory bowel disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
88 Inflammatory mediator regulation of TRP channels 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
89 Inflammatory mediator regulation of TRP channels 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
90 Influenza A 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
91 Influenza A 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
92 Influenza A 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
93 Insulin resistance 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
94 Insulin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
95 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
96 Integrin signaling 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
97 JAK-STAT signaling pathway 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
98 JAK-STAT signaling pathway 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
99 JAK-STAT signaling pathway 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
100 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
101 Kaposi sarcoma-associated herpesvirus infection 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
102 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
103 Legionellosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
104 Leishmaniasis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
105 Leishmaniasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
106 Leishmaniasis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
107 Lipid and atherosclerosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
108 Lipid and atherosclerosis 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
109 Longevity regulating pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
110 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
111 Lysosome biogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
112 Malaria 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
113 Malaria 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
114 MAPK signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
115 MAPK signaling pathway 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
116 Measles 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
117 Measles 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
118 MicroRNAs in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
119 mTOR signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
120 Natural killer cell mediated cytotoxicity 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
121 Necroptosis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
122 Necroptosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
123 Necroptosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
124 Neuroactive ligand-receptor interaction 💬
[1] NR3C1 💬 Prednisolone 💬 Prednisolone [48]  3 , 11, 13, 14, 18, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 57, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 111, 113, 145, 162, 222, 223, 251, 269, 271, 296, 299, 300 💬
125 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
126 NF-kappa B signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
127 NF-kappa B signaling pathway 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
128 NOD-like receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
129 NOD-like receptor signaling pathway 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
130 Non-alcoholic fatty liver disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
131 Non-alcoholic fatty liver disease 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
132 One carbon pool by folate 💬
[2] DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
133 One carbon pool by folate 💬
[2] DHFR, DHFR2 💬 Methotrexate sodium 💬 Methotrexate [41] 11, 13, 14, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 223, 240, 256, 270, 271, 284, 285, 286, 326, 331 💬
134 Osteoclast differentiation 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
135 Osteoclast differentiation 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
136 Osteoclast differentiation 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
137 Osteoclast differentiation 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
138 Pancreatic cancer 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
139 Pancreatic cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
140 Pathogenic Escherichia coli infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
141 Pathogenic Escherichia coli infection 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
142 Pathways in cancer 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
143 Pathways in cancer 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
144 Pathways in cancer 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
145 Pathways in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
146 Pathways of neurodegeneration - multiple diseases 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
147 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
148 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
149 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
150 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
151 Pertussis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
152 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
153 PI3K-Akt signaling pathway 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
154 PI3K-Akt signaling pathway 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
155 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
156 Prion disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
157 Prolactin signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
158 Prostate cancer 💬
[1] IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
159 Prostate cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
160 Proteasome 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
161 Proteoglycans in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
162 Pyrimidine metabolism 💬
[1] DHODH 💬 Leflunomide 💬 Leflunomide [14] 11, 40, 46, 49, 53, 54, 66, 107, 162, 223, 224, 270, 271, 300 💬
163 Rheumatoid arthritis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
164 Rheumatoid arthritis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
165 Salmonella infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
166 Shigellosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
167 Shigellosis 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
168 Shigellosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
169 Signaling pathways regulating pluripotency of stem cells 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
170 Spinocerebellar ataxia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
171 Systemic lupus erythematosus 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
172 T cell receptor signaling pathway 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
173 TGF-beta signaling pathway 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
174 Th1 and Th2 cell differentiation 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
175 Th1 and Th2 cell differentiation 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
176 Th17 cell differentiation 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
177 Th17 cell differentiation 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
178 Th17 cell differentiation 💬
[1] IL1R1 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
179 Th17 cell differentiation 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
180 Th17 cell differentiation 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
181 Th17 cell differentiation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
182 Thermogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
183 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
184 TNF signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
185 Toll-like receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
186 Toll-like receptor signaling pathway 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
187 Toxoplasmosis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
188 Toxoplasmosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
189 Transcriptional misregulation in cancer 💬
[1] IL1R2 💬 Anakinra 💬 Anakinra [22]  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 57, 84, 86, 97, 106, 107, 149, 153, 266, 299 💬
190 Tuberculosis 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
191 Tuberculosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
192 Tuberculosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
193 Type I diabetes mellitus 💬
[1] IFNG 💬 Emapalumab 💬 Emapalumab [6] 49, 50, 54, 60, 65, 107 💬
194 Type I diabetes mellitus 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
195 Type II diabetes mellitus 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
196 Viral carcinogenesis 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
197 Viral protein interaction with cytokine and cytokine receptor 💬
[1] IL6R 💬 Tocilizumab 💬 Tocilizumab [26]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 65, 86, 107, 149, 153, 223, 266, 271, 298, 331 💬
198 Yersinia infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬